MCAS and the Gut: Abdominal Pain, Diarrhea, and Nausea in Mast Cell Disease

Gastrointestinal symptoms are present in the majority of patients with mast cell activation syndrome (MCAS). Abdominal pain, nausea, vomiting, diarrhea, bloating, and cramping are not peripheral features of the disease — they are often among the most disabling symptoms, and they are frequently the reason patients first seek medical attention. Understanding why the gut is so central to MCAS, and what can be done about it, is essential for effective management.

Why the Gut Is a Primary Target in MCAS

The gastrointestinal tract contains the highest density of mast cells in the body outside of the skin. Mast cells are distributed throughout the gut wall, from the esophagus to the rectum, with particularly high concentrations in the small intestine and colon. They are strategically positioned at the interface between the gut lumen (and its contents, including food antigens, bacteria, and toxins) and the underlying immune and nervous tissue.

In healthy individuals, gut mast cells serve as sentinels — they detect pathogens and allergens and launch appropriate immune responses. In MCAS, these mast cells are dysregulated: they activate in response to stimuli that should not trigger significant degranulation, releasing histamine, tryptase, prostaglandins, leukotrienes, and other mediators into the gut wall and lumen.

The consequences of this dysregulated activation are widespread:

Increased intestinal permeability ("leaky gut"). Mast cell mediators, particularly histamine and tryptase, disrupt the tight junctions between intestinal epithelial cells, increasing gut permeability. This allows partially digested food proteins, bacterial products (lipopolysaccharide), and other luminal contents to cross the gut barrier and enter the bloodstream, potentially triggering systemic immune activation and worsening mast cell activation in a self-perpetuating cycle.

Altered gut motility. Mast cells regulate gut motility through their effects on the enteric nervous system (the "gut brain"). Mast cell mediators can either accelerate motility (causing diarrhea and urgency) or slow it (causing constipation and bloating), depending on which mediators predominate and which receptors are activated. Many MCAS patients experience alternating diarrhea and constipation, reflecting this dysregulated motility.

Visceral hypersensitivity. Mast cells sensitize the pain-sensing nerve fibers (nociceptors) in the gut wall, lowering the threshold at which normal gut sensations (distension, peristaltic contractions) are perceived as painful. This visceral hypersensitivity is the same mechanism that underlies irritable bowel syndrome (IBS), and MCAS is increasingly recognized as a significant driver of IBS in a subset of patients.

Impaired digestive enzyme function. Mast cell activation in the small intestine can impair the function of digestive enzymes and reduce absorption of nutrients, contributing to nutritional deficiencies and malabsorption symptoms.

Common GI Symptoms in MCAS

Abdominal pain is the most common GI symptom in MCAS. It is typically cramping or colicky in character, often located in the periumbilical region or lower abdomen, and frequently associated with eating. The pain may be mild and chronic or severe and episodic. Some MCAS patients experience abdominal pain severe enough to be mistaken for appendicitis or bowel obstruction.

Nausea and vomiting are present in a majority of MCAS patients. Nausea is often worse after eating (particularly high-histamine foods) and may be accompanied by early satiety. Vomiting during acute MCAS reactions is common.

Diarrhea is frequently episodic and urgent, often occurring in the context of MCAS reactions. Watery diarrhea is more common than bloody diarrhea (the latter should prompt evaluation for other causes). Some patients have chronic loose stools rather than episodic diarrhea.

Bloating and distension are very common and often severe. The combination of altered motility, increased gas production from dysbiotic bacteria, and visceral hypersensitivity creates significant abdominal distension that can be physically uncomfortable and cosmetically distressing.

Gastroesophageal reflux (GERD) occurs in many MCAS patients. Mast cell activation in the esophagus and lower esophageal sphincter contributes to acid reflux, and histamine directly stimulates gastric acid secretion through H2 receptors.

Dysphagia and esophageal spasm are less common but occur in some MCAS patients, particularly those with eosinophilic esophagitis (EoE), which has significant overlap with MCAS.

The MCAS-IBS Connection

Irritable bowel syndrome (IBS) and MCAS overlap substantially. Studies have found elevated mast cell counts and increased mast cell activation in the gut biopsies of IBS patients, and the symptom profiles of IBS and MCAS-related gut disease are nearly identical. Many patients who have been diagnosed with IBS — particularly those who do not respond to standard IBS treatments — may have underlying MCAS driving their gut symptoms.

The distinction matters clinically because the treatment approaches differ. Standard IBS treatments (low-FODMAP diet, antispasmodics, tricyclic antidepressants) may provide partial relief but do not address the underlying mast cell dysregulation. Adding mast cell-targeted treatments (H1 and H2 antihistamines, cromolyn sodium, ketotifen, low-histamine diet) often produces significantly better results in patients with MCAS-driven gut disease.

Diagnosis: When to Suspect MCAS-Related GI Disease

MCAS should be considered in patients with chronic GI symptoms when:

• Standard GI workup (colonoscopy, endoscopy, celiac testing, stool studies) is normal or non-diagnostic
• Symptoms are associated with eating, particularly high-histamine foods
• GI symptoms occur in the context of other MCAS features (flushing, urticaria, tachycardia, anaphylaxis-like reactions)
• Symptoms worsen with NSAIDs, alcohol, or other known mast cell triggers
• There are comorbid POTS, EDS, or other connective tissue/autonomic disorders
• Standard IBS treatments have failed

Diagnosis involves the same approach as MCAS generally: documentation of elevated mast cell mediators (tryptase, urine histamine, urine PGD2) during symptomatic periods, and ideally gut biopsy showing increased mast cell density or activation.

Treatment

Dietary modification is the foundation of treatment for MCAS-related gut disease. The low-histamine diet reduces the histamine load entering the gut and is the most evidence-based dietary intervention. Some patients also benefit from a low-FODMAP diet (which reduces fermentable carbohydrates that feed gut bacteria and may worsen mast cell activation through bacterial products) or a low-oxalate diet.

H1 and H2 antihistamines taken daily (not just during reactions) reduce the baseline level of histamine-mediated gut inflammation. H2 antihistamines (famotidine) are particularly important for GI symptoms because H2 receptors are highly expressed in the gut.

Cromolyn sodium (oral) is a mast cell stabilizer that is poorly absorbed from the gut, meaning it acts locally in the GI tract. Oral cromolyn is one of the most effective treatments for MCAS-related gut disease and is available in the US as a prescription medication (Gastrocrom). It is taken 30 minutes before meals.

Ketotifen is a mast cell stabilizer and H1 antihistamine that, unlike cromolyn, is absorbed systemically. It is effective for both gut and systemic MCAS symptoms.

Proton pump inhibitors (PPIs) can help with GERD symptoms but do not address the underlying mast cell activation. They should be used judiciously, as long-term PPI use has its own risks.

Probiotics may help by modulating the gut microbiome and reducing bacterial histamine production. Strains that do not produce histamine (Lactobacillus rhamnosus GG, Bifidobacterium species) are preferred; histamine-producing strains (some Lactobacillus casei and L. bulgaricus strains) should be avoided.

Low-dose naltrexone (LDN) has emerging evidence for both MCAS and IBS, potentially through its effects on the gut immune system and mast cell activity.

Managing MCAS-related gut disease requires patience and a systematic approach. Most patients see gradual improvement over weeks to months as the combination of dietary modification and medication reduces the chronic state of gut mast cell activation.